mProX™ Human JAK1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1176	Magic™ Human JAK1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

JAK1

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Immunology Research; Inflammation Research; Reproductive Research

Related Diseases

Autoinflammation, Immune Dysregulation, And Eosinophilia and Autosomal Recessive Mendelian Susceptibility To Mycobacterial Diseases Due To Partial Jak1 Deficiency. Among its related pathways are IL-9 Signaling Pathways and Overview of interferons-mediated signaling pathway

Gene ID

3716

UniProt ID

P23458

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Human tyrosine kinase JAK1 is required for the signaling of some type I and type II cytokines. It elicits signals from the gp130 receptor family, IL-2, IL-4, CNTF-R, NNT-1R, and Leptin-R families by interacting with the common gamma chain (γc) of type I cytokine receptors. It is also crucial for the type II cytokine receptor-mediated transduction of a signal by type I and type II interferons and the IL-10 family. When it comes to triggering reactions to various key cytokine receptor families, Jak1 is indispensable. In neonatal mice, loss of Jak1 results in death, potentially as a result of difficulty nursing. Cancer cells that express JAK1 can contract, which may allow the cells to spread beyond the tumor and invade other areas of the body. The customized JAK1 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Melissa

This JAK1 KD cell line has saved us time and resources. Our team is excited to delve deeper into our investigations. Jun 13 2023

chat Verified Customer

chat Shirley

I think this JAK1 KD cell line is better than many similar products already on the market. Aug 18 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 JAK1 mutation, protein levels and IFNγ response in endometrial cancer cell lines.

According to JAK1 truncating p. K860fs mutation and JAK1 protein loss, immunoblot demonstrating downstream STAT1 activation, activating Y701 phosphorylation and HLA class I heavy chain levels in response to recombinant IFNγ (75 ng/ml for 16 hours) in endometrial cancer cell lines. The conventional molecular weights are displayed to the right of the panels.

Ref: Glaire, Mark A., et al. "Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape." The Journal of pathology 257.3 (2022): 340-351.

Pubmed: 35262923

DOI: 10.1002/path.5894

Research Highlights

Cytokines that rely on JAK1 signaling to support receptor activator of NF-κB ligand production in osteoblasts and T cells-thereby promoting osteoclastogenesis-are also necessary for maintaining bone homeostasis. Here, it's unclear how much JAK1 contributes in comparison to other kinases.
Spinelli, Francesca Romana, Robert A. Colbert, and Massimo Gadina. "JAK1: Number one in the family; number one in inflammation?." Rheumatology 60.Supplement_2 (2021): ii3-ii10.
Pubmed: 33950229 DOI: 10.1093/rheumatology/keab024

Our results show that in two mouse models of HLH, the deleterious effects of macrophage overactivation are suppressed by ruxolitinib at clinically relevant levels. The findings might be easily applied to the treatment of primary and possibly even secondary types of HLH in the clinic.
Maschalidi, Sophia, et al. "Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice." Blood, The Journal of the American Society of Hematology 128.1 (2016): 60-71.
Pubmed: 27222478 DOI: 10.1182/blood-2016-02-700013